What type of study is this?

September 10, 2025Frontiers in ImmunologyOpen Access

A multi-cohort validated OXPHOS signature predicts survival and immune profiles in grade II/III glioma patients

View Full Paper

Ask AI

Bookmark

Authors

This analysis identifies molecular subtypes and a prognostic signature in grade II/III gliomas, suggesting OXPHOS may inform treatment strategies.

The four-gene prognostic signature links OXPHOS to patient outcomes, enhancing survival predictions for glioma patients.
C2 subtype demonstrates poorer prognosis and higher immune scores, indicating a need for tailored therapies.
Utilizing 200 OXPHOS-related genes, this analysis establishes novel molecular subtypes among glioma samples.
The findings support the role of OXPHOS in glioma progression, highlighting new targets for precision oncology.

Mou et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This analysis identifies molecular subtypes and a prognostic signature in grade II/III gliomas, suggesting OXPHOS may inform treatment strategies.